S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
BioHarvest Sciences Inc., a company specializing in pharmaceutical preparations, has filed a report with the United States Securities and Exchange Commission (SEC) disclosing a significant corporate update. The Form 6-K, submitted today, indicates a material change report dated January 22, 2025. According to InvestingPro data, the company has demonstrated remarkable revenue growth of 112% over the last twelve months, with an impressive gross profit margin of 54%.
The Vancouver-based company, previously known as Canna-V-Cell Sciences Inc. and before that as Midnight Star Ventures Corp., has its principal executive offices at 1140-625 Howe Street. According to the filing, BioHarvest Sciences operates under the industrial classification of Pharmaceutical (TADAWUL:2070) Preparations, with a fiscal year ending December 31. The company's stock has shown significant volatility, trading between $0 and $7.70 over the past 52 weeks.
The specific nature of the material change was not detailed in the summary provided. However, the filing of such a report typically covers significant events that could include changes in the company's operations, financial condition, or corporate structure that could influence the value of its securities.
The company's revenue has grown by a noteworthy 111.68% over the past year, with analysts predicting continued sales growth. BioHarvest launched its CDMO Services division, partnered with ingredient solutions leader Tate & Lyle, and saw a two-fold increase in its VINIA® capsule business in 2024. Furthermore, the company successfully rolled out VINIA Inside products, aiming to reach a wider consumer base.
BioHarvest's Direct-to-Consumer (D2C) Products division also experienced growth, concluding 2024 with about 50,000 active subscribers in the USA and an exit run rate nearing US$30 million. The firm expanded its VINIA® offerings with the introduction of Functional Superfood Coffee and tea lineups. Future plans include Nespresso and K-Cup compatible products, as well as VINIA SUPER-CHEWS aimed at a younger, active demographic.
Investments in an 80,000 square foot corporate campus in Yavneh, Israel, and the digitization of production processes have improved gross margin profiles from 44% in Q3 2023 to 56% in Q3 2024, with expectations to surpass 60% in 2025.
BioHarvest maintains impressive gross profit margins of 54%, despite operating with moderate debt levels. The company aims for adjusted EBITDA profitability in the second half of 2025. These are recent developments in the company's ongoing growth journey.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.